Amryt Pharma PLC - biopharmaceutical company - Says the French Ministry of Social Affairs & Health has approved Myalepta for reimbursement in France as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy. Myalepta received marketing authorisation from the European Medicines Agency in 2018.
"Today's news represents further progress in our efforts to grow the geographic reach of our commercial products in both existing and new territories," says Chief Executive Joe Wiley.
Current stock price: 211.00 pence, closed down 3.2% on Monday
Year-to-date change: up 12%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
